Open Access

Does zafirlukast reduce future risk of asthma exacerbations in adults? Systematic review and meta-analysis

Multidisciplinary Respiratory Medicine20149:30

DOI: 10.1186/2049-6958-9-30

Received: 8 February 2014

Accepted: 6 May 2014

Published: 28 May 2014

Abstract

Background and objective

The purpose of asthma management is to achieve a total asthma control that involves current control and future risk. It has proven efficacy in reducing asthma exacerbations, but the effect size of zafirlukast for asthma exacerbations of various severity is not systematically explored.

Methods

Randomized controlled trials were searched in PubMed Central, Web of Science, and Embase, where zafirlukast prevented asthma exacerbations in adults. The primary outcome was asthma exacerbations, the secondary outcomes were asthma exacerbations requiring systemic corticosteroids and emergency visits, respectively. Odds ratio (OR) with 95% confidence intervals (CI) were pooled.

Results

Twelve trials were identified. As first-line therapy, compared to those having placebo, the patients with chronic asthma receiving zafirlukast experienced statistically lower asthma exacerbations (OR = 0.68, 95% CI = [0.45, 1.00]), but it was not found that zafirlukast was superior to placebo in asthma exacerbations requiring systemic corticosteroids (OR = 0.76, 95% CI = [0.45, 1.29]). Furthermore, zafirlukast was inferior to ICs in asthma exacerbations (OR = 2.11, 95% CI = [1.35, 3.30]) and requiring systemic corticosteroids (OR = 3.71, 95% CI = [1.82, 7.59]). As add-on therapy, zafirlukast was not superior to placebo in asthma exacerbations (OR =0.99, 95% CI = [0.54, 1.81] and requiring emergency visits (OR = 0.72, 95% CI = [0.18, 2.99]). Intriguingly, there was not a significant difference in asthma exacerbations between zafirlukast and ICs (OR = 1.12, 95% CI = [0.53, 2.34]).

Conclusions

Our study suggests that zafirlukast, as the first-line therapy, significantly reduces mild to moderate but not severe asthma exacerbations. In the add-on regimen, zafirlukast could not reduce asthma exacerbations, which would perhaps result from small sample size and needs to be further studied.

Keywords

Asthma exacerbations First-line and add-on therapy Meta-analysis Systematic review Zafirlukast

Introduction

Asthma is a chronic inflammatory disorder of airways closely associated with airway hyperresponsiveness. It is estimated that around 300 million people suffer from asthma and the burden of this disease to governments, health care systems, families, and patients is increasing worldwide [1, 2]. Despite advances in knowledge of the pathophysiology of asthma and availability of effective therapy, currently asthma cannot be cured yet.

The goal of asthma treatment is to achieve and maintain asthma optimal control, which includes current control and long-term components referred to as “risk” or “future risk” since 2009 [3]. Asthma control is evaluated by a global assessment of asthma symptoms, reliever medicine use, lung function, and the frequency/severity of exacerbations. It is disappointing that only 2% of asthma patients are considered controlled across eight Asia-Pacific countries and Hong Kong in real world settings when control is assessed using the Global Initiative for Asthma (GINA) classification [4]. Asthma exacerbations, as the most important future risk, are recognized as a common clinical manifestation in patients with severe asthma, and are known to increase the risk of asthma mortality [5]. Hence, in recent years to prevent asthma exacerbations has been identified as an important component of establishing ideal asthma control in all asthma treatment guidelines. Inhaled corticosteroids (ICs) and combination of ICs/long-acting β2-agonists (LABA) are the mainstay of therapy for reducing asthma exacerbations including the severe ones, but some patients require additional treatment or prefer not to use ICs. In such patients, leukotriene receptor antagonist (LTRA), is a promising alternative to ICs therapy.

Although LTRA has been proven to be effective in improving asthma control in clinical practice, few studies systematically focused on effects of LTRA on future asthma outcomes, such as exacerbations and their various types. Furthermore, the relative effect size of LTRAs for prevention of future risk of asthma exacerbations remains unclear. Also because there is a great heterogeneity in pooled data of different types of LTRA, such as montelukast, zafirlukast, panlukastandzileuton [6]. This systematic review and meta-analysis is aimed to explore effects of zafirlukast, as first-line and add-on therapy, on prevention of asthma exacerbations in adults.

Methods

Search strategy and selection criteria

We searched electronic databases including PubMed (1991 to June 2013), Embase (1992 to June 2013) and Web of Science (1992 to June 2013) for randomized controlled trials (RCTs) using a comprehensive search strategy including the following keywords: “zafirlukast AND (asthma or wheezing), Limits Activated: Randomized Controlled Trial (RCT)”. We reviewed reference lists of all included studies, systematic reviews and narrative reviews to identify potentially relevant citations. There was no limitation on language or year of publication.

Trials were included if they met the following criteria: they were randomized controlled trials comparing zafirlukast versus placebo or other active drugs and reporting at least one asthma exacerbation. The trials were excluded if the patients were hospitalized for acute asthma because the primary outcome of this study for zafirlukast in treating asthma included hospitalization for asthma exacerbation. After exclusion of duplicates, two reviewers (C.F.C. and Y.L.) reviewed the full text of all citations with titles and abstracts that seemed to fit the criteria of inclusion. Irrelevant citations or not randomized controlled trials were not reviewed in full text. The number of citations rejected and the reasons for rejection were tracked.

Data extraction and quality assessment

We reviewed each eligible citation, and obtained the full text of all definite of possible randomized controlled trials. From each article we extracted details regarding authors, year of publication, sex, sample size, sample size calculation, standard treatments, interventions as the first-line or add-on therapies, outcomes, adverse events, and intention to treat analysis and so on.

The methodological quality of included trials was assessed independently by two reviewers (CFC and YL). If information was not reported adequately, authors or sponsors of each included trial were contacted to acquire the accuracy of the methodology and primary data. The quality of the methods of each trial was assessed with the Cochrane Collaboration’s tool for assessing risk of bias [7]. Our judgments of high, low, and unclear risk of bias were corroborated by citations from trial reports, correspondence, or summarized information from the relevant sections of the individual study reports. Any disagreement between reviewers was resolved by consensus or by the third reviewer (G.W.).

Primary and secondary outcomes

In the meta-analysis assessing the prevention of zafirlukast from asthma exacerbations, the number of asthma exacerbations was a priori specified primary outcome so as the number of detailed different exacerbations such as requiring systemic corticosteroids, whereas emergency visits and hospitalizations were identified as secondary outcomes.

Statistical analysis, and assessment and evaluation of the evidence quality

The included trials were divided into two types of analyses stratified by zafirlukast as the first-line or the add-on therapies. The mean daily dose of ICs was converted in “microgram (μg) of beclomethasone equivalent”. Asthma exacerbations as dichotomous variables were reported as odds ratio (OR).

Heterogeneity was assessed by means of the Cochran Q method and by the test of inconsistency (I2). A random effects model was used if the Q statistic (p < 0.1) or I2 (> 50%) was significant, or we used a fixed effects model. We carried out subgroup analysis to assess the source of heterogeneity and we assessed the presence of publication bias visually with a funnel plot. Differences in bias risk and number needed to treat (NNT) were calculated to assess clinical significance. All estimates were reported with 95% confidence intervals (CI) and all p were 2-tailed. The meta-analysis was performed with Stata 11.0 (Stata Corp LP, College Station, Texas), and the risk bias of the methodological quality was assessed using RevMan 5.1 (Cochrane Review Manager, The Cochrane Collaboration, Oxford, UK).

The quality of the evidence related to the estimation of benefits and disadvantages in asthma exacerbation in adult population requiring oral/parenteral corticosteroid or emergency visits followed the suggestions of the GRADE Working Group (http://www.gradeworkinggroup.org/index.htm) by adopting the use of GradePro software 3.6 (http://ims.cochrane.org/revman/gradepro).

Results

Trials included, study characteristics and quality of reporting

The search strategy initially yielded 313 citations. Figure 1 shows details of study identification, inclusion and exclusion. Twelve unique trials with 4,398 participants which met the inclusion criteria came into statistical analysis [819]. All the trials recruited adults and adolescents. The characteristics of the included studies are listed in Table 1. The intervention period ranged from 4 to 48 weeks (median: 26 weeks). There were two types of interventions for zafirlukast, and they were first-line (n = 10) or add-on (n = 4) treatments. The dosage of zafirlukast was administrated 20 mg twice a day, except for two trials [14, 19], where patients were treated with zafirlukast 80 mg twice daily, or were given 5 mg, 10 mg and 20 mg twice daily, respectively. The number of patients included in these studies varied between 38 and 762. In included studies with chronic persistent asthma, FEV1% of predicted value at baseline was more than 45%. In general, rescue β2-agonists were permitted.
Figure 1

Flow diagram of trial selection and details of study identification, inclusion and exclusion.

Table 1

Characteristic of the included trials

Study ID

Age mean ± SD [Range], y

Gender (F/M)

Intervention

Standard treatments

Compliance (%)

FEV1%

Run in period

Treatment duration

Type of intervention

Reported outcomes

          

AE

AES

AEE

Boushey HA 2005 [8]

T: 33.6 ± 11.1

T: 47/29

T: Z 20 mg + IP bid

IB 800 ug bid × 10D or prednisone × 5D if asthma worsened

> 90

≥ 70

4 weeks

48 weeks

First-line/add-on

+

+

C1: 33.2 ± 9.5

C1: 48/25

C1: IB 200 ug + OP bid

C2: 32.0 ± 10.5

C2: 43/33

C2: IP + OP bid

Huang CJ 2003 [9]

T: 58.6 ± 3.0

T: 8/9

T: Z 20 mg bid

IB (≥ 400 μg/day or equivalent) + SABA

NR

Moderate

2 weeks

4 weeks

Add-on

+

+

C: 56.9 ± 2.8

C: 7/7

C: Placebo 20 mg bid

Brabson JH 2002 [10]

T: 35 ± 16

T: 141/75

T: Z 20 mg bid

Albuterol as needed

≥ 88

60-85

8 days

6 weeks

First-line

+

+

+

C: 36 ± 14

C: 134/90

C: IFP 88 ug bid

Nathan RA 2001 [11]

T: 32

T: 65/85

T: Z 20 mg bid

Albuterol as needed

NR

50-80

7-14 days

4 weeks

First-line

+

C: 31

C: 79/65

C: Fluticasone 88 ug bid

Busse W 2001 [12]

T: 12-75

T: NR

T: Z 20 mg + IP bid

Albuterol as needed, or oral or parental corticosteriods for AE

NR

50-80

8-14 days

12 weeks

First-line/add-on

+

+

C: 12-75

C: NR

C1: IFP 88 ug + OP bid

  

C2: IP + OP bid

Kim KT 2000 [13]

T: 32.9

T: 127/89

T: Z 20 mg + IP bid

Albuterol as needed

88

60- 85

1 week

6 weeks

First-line

+

+

+

C: 35.5

C: 135/86

C: IFP 88 ug bid

Virchow JCJr 2000 [14]

T: 47.4 ± 12.6

T: 85/95

T: Z 80 mg bid

Beclomethasone ≥ 1200 ug/day or equivalent) + SABA

T: 95

50-75

2 weeks

6 weeks

Add-on

+

C: 49.2 ± 12.9

C: 98/90

C: Placebo 80 mg bid

C: 94

Bleecker ER 2000 [15]

T: 31

T: 113/107

T: Z 20 mg bid

Albuterol as needed

92

50-80

8-14 days

12 weeks

First-line

+

C: 31

C: 112/119

C: IFP 88 ug bid

Busse W 1999 [16]

T: 36.9

T: 85/60

T: Z 20 mg bid

Albuterol as needed

NR

50-80

7-14 days

4 week

First-line

+

C: 38.6

C: 77/67

C: SX 42 ug bid

Nathan RA 1998 [17]

T: 33.2

T: 127/104

T: Z 20 mg bid

SABA as needed

NR

45-80

2-3 weeks

13 weeks

First-line

+

+

C: 32.1

C: 132/91

C: Placebo 20 mg bid

Fish JE 1997 [18]

T: > 12

T: 220/294

T: Z 20 mg bid

Albuterol as needed

NR

> 55

7-14 days

13 weeks

First-line

+

C: > 12

C: 102/146

C: Placebo 20 mg bid

Spector SL 1994 [19]

T: Z1: 37, Z2: 35, Z3: 36, C: 36

T: Z1: 18/52, Z2: 23/45, Z3: 18/50, C: 20/50

T: Z1: 20 mg bid, Z2: 10 mg bid, Z3: 5 mg bid, C: Placebo bid

Albuterol as needed

NR

40-75

2 weeks

6 weeks

First-line

+

AE, asthma exacerbations; AEE, asthma exacerbation require emergency visits; AES, asthma exacerbation require systematic corticosteroid; bid, twice daily; C, control group; D, days; F, female; IB, inhalation budesonide; IFP, inhalied fluticasone propionate; IP, inhalation of placebo; M, male; NR, not reported; OP, oral placebo; SABA, short β2 agonist; SD, standard deviation; SX, Salmeterolxinafoate; T, treatment group; y, year; Z, zafirlukast; +, positive report; —, negative report.

All the included trials were randomized and controlled. Table 2 shows an overview of the risk bias of each trial. There was no conflict of interest among eligible studies. Double blinding was used in all trials. On the whole, most of the included studies were of high methodological quality.
Table 2

Methodological quality of included studies

Study

Randomly assigned

Allocation concealment

Multi- center

Blinding

Complete outcome data adequately addressed

Free of selective outcomes reporting

Other bias

Intention to treat

Sample size calculation

Power

Conflict of interest

Boushey 2005 [8]

Yes

Yes

Yes

Double-blind

Yes

Unclear

Unclear

No

Yes

0.90

No

Huang 2003 [9]

Yes

Yes

No

Double-blind

Yes

Unclear

Unclear

No

No

NA

No

Brabson 2002 [10]

Yes

Yes

Yes

Double-blind

Yes

Unclear

Unclear

Yes

Yes

0.80

No

Nathan 2001 [11]

Yes

Yes

Yes

Double-blind

Yes

Unclear

Unclear

No

Yes

0.80

No

Busse 2001 [12]

Yes

Yes

No

Double-blind

Yes

Unclear

Unclear

No

Yes

0.80

No

Kim 2000 [13]

Yes

Yes

No

Double-blind

Yes

Unclear

No

Yes

Yes

0.80

No

Virchow 2000 [14]

Yes

Yes

Yes

Double-blind

Yes

Unclear

Unclear

No

No

NA

No

Bleecker 2000 [15]

Yes

Yes

Yes

Double-blind

Yes

Unclear

No

Yes

Yes

0.80

No

Busse 1999 [16]

Yes

Yes

Yes

Double-blind

Yes

Unclear

Unclear

Yes

Yes

0.80

No

Nathan 1998 [17]

Yes

Yes

Yes

Double-blind

Yes

Unclear

Unclear

No

Yes

0.90

No

Fish 1997 [18]

Yes

Yes

Yes

Double-blind

Yes

Unclear

Unclear

No

Yes

0.90

No

Spector 1994 [19]

Yes

Yes

Yes

Double-blind

Yes

Unclear

No

No

Yes

0.90

No

NA, not available.

Outcomes for meta-analysis

First-line therapy

The primary and secondary outcomes are shown in Figure 2. Compared to those having placebo, the patients with chronic asthma receiving zafirlukast experienced statistically lower asthma exacerbations (OR = 0.68, 95% CI = [0.45, 1.00]). However, zafirlukast as the first-line therapy in chronic asthma was not superior to placebo in requiring systematic corticosteroids for asthma exacerbation (OR = 0.76, 95% CI = [0.45, 1.29]). Furthermore, zafirlukast was inferior to ICs in patients experiencing asthma exacerbations (OR = 2.11, 95% CI = [1.35, 3.30]) and asthma exacerbations requiring systematic corticosteroids (OR = 3.71, 95% CI = [1.82, 7.59]) but not in those requiring emergency visits (OR = 1.07, 95% CI = [0.46, 2.51]).
Figure 2

Pooled odds ratio of patients experiencing different types of asthma exacerbations, comparing controlled drugs with zafirlukast. Trials stratified according to controlled treatments (ICs and placebo) and intervention types. OR, odds ratio.

In placebo-controlled studies, only two trials which had met the inclusion criteria about patients requiring systematic corticosteroids for asthma exacerbations came into meta-analysis, so we could not perform subgroup and sensitivity analysis. Our subgroup and sensitivity analysis in ICs-controlled studies indicated that long-term ICs with more than 12 weeks did not get much more benefit in emergency visits in comparison to that with less than 12 weeks (OR = 2.56, 95% CI = [0.80, 8.20] vs. OR = 1.07, 95% CI = [0.46, 2.51]).

Add-on therapy

When zafirlukast was taken as an add-on therapy, we unexpectedly found it was not superior to placebo in asthma exacerbations (OR =0.99, 95% CI = [0.54, 1.81] and emergency visits (OR = 0.72, 95% CI = [0.18, 2.99]). Intriguingly, there was not a significant difference in asthma exacerbations between zafirlukast and ICs (OR = 1.12, 95% CI = [0.53, 2.34].

Assessment and recommendation of zafirlukast for prevention of asthma exacerbations

The details are shown in Table 3. We assessed the asthma exacerbations and the participants who required emergency visits or needed systemic corticosteroids because of asthma exacerbations. According to the methodology of each trial, the quality of evidence of zafirlukast as first-line treatment compared with placebo, first-line/add-on treatment compared with ICs was of low or moderate quality. The trials failed to undertake intention-to-treat analysis and publication of bias in the funnel plot among the trials contributed to decrease the quality of evidence.
Table 3

Assessment of benefits and disadvantages in asthma exacerbation

Clinical outcomes

Comparisons

Therapy type

Illustrative comparative risk

Relative effect (95% CI)

No. of participants (studies)

Quality of evidence (GRADE)

With comparator

With intervention

Asthma exacerbation

Zafirlukast vs. placebo

First-line

92/1000

62/1000 (44 to 92)

OR = 0.68 [0.45, 1.00]

1,255 (n = 4)

Low1

Zafirlukast vs. ICs

First-line

31/1000

64/1000 (42 to 96)

OR = 2.11 [1.35, 3.30]

1,963 (n = 6)

Moderate2

Zafirlukast vs. ICs

Add-on

83/1000

92/1000 (46 to 175)

OR = 1.12 [0.53, 2.34]

353 (n = 2)

Low3

Zafirlukast vs. placebo

Add-on

121/1000

120/1000 (69 to 200)

OR = 0.96 [0.54, 1.81]

383 (n = 3)

Low4

Asthma exacerbation requiring systemic corticosteriod

Zafirlukast vs. placebo

First-line

108/1000

86/1000 (40 to 186)

OR = 0.76 [0.45, 1.29]

544 (n = 2)

Low5

Zafirlukast vs. ICs

First-line

18/1000

64/1000 (32 to 123)

OR = 3.71 [1.82, 7.59]

1,089 (n = 3)

Moderate6

Asthma exacerbation requiring emergency treatment

Zafirlukast vs. ICs

First-line

22/1000

23/1000 (10 to 53)

OR = 1.07 [0.46, 2.51]

994 (n = 3)

Low7

 

Zafirlukast vs. placebo

Add-on

60/1000

44/1000 (11 to 159)

OR = 0.72 [0.18, 2.99]

163 (n = 3)

Low8

CI,= confidence intervals; ICs,= inhaled corticosteroids; OR, odds ratio.

1 (−1 limitations) (−1 publication bias). Four trials (Boushey HA 2005, Busse W 2001, Fish JE 1997, Nathan RA 1998) have high quality, but all of them fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Four trials were included, from the funnel plot we strongly suspected there was publication bias.

2 (−1 limitations). Busse W 2001 and Nathan RA 1998 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality).

3 (−1 limitations) (−1 publication bias). Busse W 2001 and Boushey HA 2005 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Only two trials were included, from the funnel plot we strongly suspected there was publication bias.

4 (−1 limitations) (−1 publication bias). Three trials (Boushey HA 2005, Busse W 2001, Huang CJ 2003) have high quality, but all of them fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Three trials were included, from the funnel plot we strongly suspected there was publication bias.

5 (−1 limitations) (−1 publication bias).Busse W 2001 and Nathan RA 1998 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Only two trials were included, from the funnel plot we strongly suspected there was publication bias.

6 (−1 limitations) (−1 publication bias) (+1 large effect). Busse W 2001 fails to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Three trials were included, from the funnel plot we strongly suspected there was publication bias. Large effect (M-H pooled OR = 3.712) in the absence of other methodological limitations), so upgrading quality of evidence.

7 (−1 limitations) (−1 publication bias).Boushey HA 2005 fails to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Trials were included, from the funnel plot we strongly suspected there was publication bias.

8 (−1 limitations) (−1 publication bias).Boushey HA 2005 and Huang CJ 2003 fail to adhere to an intention-to-treat analysis, so suggesting high likelihood of bias (−1 of quality). Trials were included from the funnel plot we strongly suspected there was publication bias.

Discussion

According to GINA report, the goal of asthma management is to achieve and maintain optimal asthma control [2]. Recently, the concept of asthma control has been extended to include an assessment of future risk in addition to the previous focus on the current impairment from asthma [20, 21]. Despite advances in knowledge of the pathophysiology of asthma and via availability of effective therapy, asthma cannot currently be cured yet. As the most important factors in future risk of asthma, asthma exacerbations are common in asthmatic patients’ life, and constitute a major burden on health care resources. In patients with chronic mild to moderate asthma, zafirlukast significantly reduced asthma exacerbations in the first-line regimen when compared to placebo, but we did not find that zafirlukast was superior to placebo in asthma exacerbations in add-on regimen. Furthermore, zafirlukast was inferior to ICs in reducing asthma exacerbations and asthma exacerbations requiring systemic corticosteroids. It suggested that there was no absolute advantage from zafirlukast in relieving severe asthma attack such as asthma exacerbations requiring systemic corticosteroids or emergency visits.

Preventing recurrent exacerbations is an important goal in asthma therapy. Zafirlukast showed an overall beneficial effect on the symptoms of chronic asthma as measured by asthma exacerbations and other parameters when compared to placebo. Though there is a less-stringent definition for asthma exacerbation (based on patient’s current therapy change, oral or inhaled steroids use, worsening symptoms, emergency room treatment or hospitalization, or rescue albuterol use), definitions of a mild or moderate asthma exacerbation are justifiable according to a recently published ATS/ERS statement [20]. On the basis of ATS/ERS, severe asthma exacerbations can be defined as events that require urgent action on the part of the patient and physician to prevent a serious outcome, such as use of systemic corticosteroids, hospitalization or death from asthma; moderate exacerbations as events that result in a temporary change in treatment, in an effort to prevent the exacerbation from becoming severe; and mild exacerbations that are only just outside the normal range of variation in symptoms or changes in flow rates for the individual patient and may reflect transient loss of asthma control. In our study, the available data demonstrated that zafirlukast only decreased the risk of mild and moderate asthma exacerbations, but not severe asthma exacerbations, such as requiring systemic corticosteroids and emergency visits in chronic persistent asthma. Although zafirlukast was superior to placebo in reducing the risk of asthma exacerbations, our results indicated that patients receiving low-dose ICs from 352 to 400 ug daily had fairly fewer asthma exacerbations than those taking zafirlukast. It was consistent with Ducharme FM’s results that, in adults with mild to moderate chronic asthma, the risk of exacerbations requiring systemic glucocorticoids was 60% higher with daily oral leukotriene receptor antagonists than with doses of ICs equivalent to 400 ug/day inhaled beclometasone [6].

ICs were considered as the first-line treatment for patients with moderate to severe persistent asthma, but some patients require additional treatments or prefer not to use ICs. Our study manifested that the addition of zafirlukast to ICs could not reduce the asthma exacerbations as future risk of asthma outcomes. It indicated that zafirlukast, as an add-on therapy, might be possibly associated with improving asthma symptoms but not asthma exacerbations in future. Reid et al. found that zafirlukast significantly improved FEV1 and PEF, and reduced morning waking with asthma and β2-agonist puffs [22]. In bronchial challenge studies, zafirlukast attenuated the lower airway symptoms and pulmonary response to cat challenge [23, 24]. Asthma is a complex multifactorial disorder involving a variety of different mechanisms. Environmental exposure and genetic background play a major role in development of asthma and triggering asthma symptoms. Genetic studies have produced heterogeneous results with little replication. More than 100 genes had been reported in connection to asthma or asthma phenotypes since the first study linking a genetic locus to asthma in 1989 [25]. Our recent study systemically explored the network of asthma-related genes where three hundred and twenty-six genes were identified [26]. The poor asthma control is related to deteriorative airway inflammation, asthma-related comorbidities such as obesity, rhinitis, gastroesophageal reflux disease, obstructive sleep apnoea, and exacerbation risk which is an important component to investigate asthma control [27].

In our systematic review, 10 out of twelve trials definitely described subjects characterized by no smoking, but there was not enough information to identify the status of smoking in other two trials [10, 11]. Active smoking is associated with an increased morbidity from asthma and impairs the response to ICs [28, 29]. The children exposed to environmental tobacco smoking had impaired recovery after hospitalization for acute asthma [30]. Extensive studies reveal that diet, particularly breast-feeding, is related to the development of asthma. Atopy is an independent risk factor of occupational asthma [31]. Body mass index (BMI) is an important independent predictor of asthma development and poor asthma control and asthma outcome [31], but we did not perform the subgroup analysis because only one trial provided the information on BMI [8]. More available data are needed to reveal the effect of zafirlukast on asthma exacerbations in patients with different BMI. Compared to normal weight asthmatics, the obese children are more likely to have severe disease and airflow obstruction [32].

There are sorts of inflammatory cells and mediators related to asthma mechanisms. An important role in airways inflammation is played by cysteinylleukotrienes, which are powerful agents inducing bronchoconstriction, mucus hypersecretion and airways hyperresponsiveness, and act as chemoattractants for eosinophils in the airways [33]. In patients with mild to moderate persistent asthma, zafirlukast, one of leukotriene receptor antagonists, produced rapid improvement in pulmonary function and daytime asthma symptoms, meanwhile decreasing the need for rescue therapy with β2-agonist and improving asthma control when combined with ICs [34]. Unexpectedly, we did not find that zafirlukast was superior to placebo in asthma exacerbations and emergency visits in either the first-line and add-on therapies. Furthermore, we did not find difference in asthma exacerbations between zafirlukast and ICs in add-on regimens. However, because of small sample size, it does not seem completely believable that zafirlukast was not superior to placebo in asthma exacerbations requiring systemic corticosteroids, and there was no significant difference in emergency visits for asthma exacerbations between zafirlukast and ICs in the first-line regimen. Additionally, all results from comparisons between zafirlukast, ICs and placebo in the add-on regimens were also somewhat unreliable for a low power. This suggests that more randomized controlled trials or larger sample size are needed to identify these difference among zafirlukast, ICs and placebo.

Our study has some limitations. First, the small number of trials could have lowered the power and lead to relative wide confidence intervals also precluding meta-regression analysis although high quality randomized controlled trials were included. Second, as it is well known, smoking, obesity, allergen, adherence and age are factors modifying the response to antiasthma medications, but this information was not available to be further analyzed.

Conclusions

This systematic review included 12 randomized controlled trials to assess the efficiency of zafirlukast in preventing asthma exacerbations as future risk in chronic persistent mild to moderate asthma. Our results showed that zafirlukast could decrease risk of mild and moderate but not severe exacerbations as the first-line regimen. Furthermore, it was evidently inferior to ICs in any kinds of exacerbations. Because it has not enough available information to support subgroup and sensitivity analysis, more trials are needed to confirm these conclusions that would benefit the asthma patients in clinical practice.

Abbreviations

ATS: 

American Thoracic Society

CI: 

Confidence interval

ERS: 

European Respiratory Society

FEV1

Forced expiratory volume in one second

FEV1% of predicted: 

Predicted of forced expiratory volume in one second percentage

GRADE: 

Grading of Recommendations Assessment, Development, and Evaluation

GINA: 

Global Initiative for Asthma

ICs: 

Inhaled corticosteroids

LTRAs: 

Leukotriene receptor antagonists

OR: 

Odds ratio

RCTs: 

Randomized controlled trials.

Declarations

Funding

This study was partly supported by National Natural Science Foundation of China (30971326, 81241002 and 81370122), Sichuan Youth Science and Technology Foundation (No. 2010JQ0008), Youth Science Funding of Sichuan University (2011SCU04B17) and Program for New Century Excellent Talents in University (NCET-12-0380).

Authors’ Affiliations

(1)
Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University

References

  1. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004, 59 (5): 469-478. 10.1111/j.1398-9995.2004.00526.x.View ArticlePubMedGoogle Scholar
  2. Global strategy for asthma management and prevention. 2011,http://www.ginasthma.org,
  3. Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, De Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szefler SJ, Sullivan SD, Thomas MD, Wenzel SE, Reddel HK: A new perspective on concepts of asthma severity and control. Eur Respir J. 2008, 32 (3): 545-554. 10.1183/09031936.00155307.View ArticlePubMedGoogle Scholar
  4. Thompson PJ, Salvi S, Lin J, Cho YJ, Eng P, Abdul Manap R, Boonsawat W, Hsu JY, Faruqi RA, Moreno-Cantu JJ, Fish JE, Ho JC: Insights, attitudes and perceptions about asthma and its treatment: Findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. Respirology. 2013, 18 (6): 957-967. 10.1111/resp.12137.View ArticlePubMedGoogle Scholar
  5. Jorgensen IM, Jensen VB, Bulow S, Dahm TL, Prahl P, Juel K: Asthma mortality in the Danish child population: risk factors and causes of asthma death. Pediatr Pulmonol. 2003, 36 (2): 142-147. 10.1002/ppul.10305.View ArticlePubMedGoogle Scholar
  6. Ducharme FM: Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003, 326 (7390): 621-10.1136/bmj.326.7390.621.PubMed CentralView ArticlePubMedGoogle Scholar
  7. The Cochrane collaboration: Cochrane handbok for systematic reviews of interventions version 5.0.0.2008.http://www.cochrane-handbook.org,
  8. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RFJ, Leone FT, Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, Szefler SJ, Wechsler ME, Israel E: Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005, 352 (15): 1519-1528. 10.1056/NEJMoa042552.View ArticlePubMedGoogle Scholar
  9. Huang CJ, Wang CH, Liu WT, Yang MC, Lin HC, Yu CT, Shiao CJ, Tan CC, Yang CK, Kuo HP: Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. Chang Gung Med J. 2003, 26 (8): 554-560.PubMedGoogle Scholar
  10. Brabson JH, Clifford D, Kerwin E, Raphael G, Pepsin PJ, Edwards LD, Srebro S, Rickard K: Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. Am J Med. 2002, 113 (1): 15-21. 10.1016/S0002-9343(02)01099-9.View ArticlePubMedGoogle Scholar
  11. Nathan RA, Bleecker ER, Kalberg C: A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am J Med. 2001, 111 (3): 195-202. 10.1016/S0002-9343(01)00800-2.View ArticlePubMedGoogle Scholar
  12. Busse W, Wolfe J, Storms W, Srebro S, Edwards L, Johnson M, Bowers BW, Rogenes PR, Rickard K: Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. J Fam Pract. 2001, 50 (7): 595-602.PubMedGoogle Scholar
  13. Kim KT, Ginchansky EJ, Friedman BF, Srebro S, Pepsin PJ, Edwards L, Stanford RH, Rickard K: Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2000, 85 (5): 398-406. 10.1016/S1081-1206(10)62555-0.View ArticlePubMedGoogle Scholar
  14. Virchow JC, Prasse A, Naya I, Summerton L, Harris A: Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000, 162 (2 Pt 1): 578-585.View ArticlePubMedGoogle Scholar
  15. Bleecker ER, Welch MJ, Weinstein SF, Kalberg C, Johnson M, Edwards L, Rickard KA: Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy ClinImmunol. 2000, 105 (6 Pt 1): 1123-1129.View ArticleGoogle Scholar
  16. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA: Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol. 1999, 103 (6): 1075-1080. 10.1016/S0091-6749(99)70182-X.View ArticlePubMedGoogle Scholar
  17. Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WJ, Galant SP, Hanby LA, Kemp JP, Kylstra JW, Nayak AS, O’Connor JP, Schwartz HJ, Southern DL, Spector SL, Williams PV: Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol. 1998, 102 (6 Pt 1): 935-942.View ArticlePubMedGoogle Scholar
  18. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM: Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The ZafirlukastTrialists Group. Clin Ther. 1997, 19 (4): 675-690. 10.1016/S0149-2918(97)80092-6.View ArticlePubMedGoogle Scholar
  19. Spector SL, Smith LJ, Glass M: Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J RespirCrit Care Med. 1994, 150 (3): 618-623. 10.1164/ajrccm.150.3.8087328.View ArticleGoogle Scholar
  20. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, De Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE: An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009, 180 (1): 59-99. 10.1164/rccm.200801-060ST.View ArticlePubMedGoogle Scholar
  21. Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H, Fu JJ, Wang L, Gibson PG, Wang G: The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. J Allergy Clin Immunol. 2013, 131 (3): 695-703. 10.1016/j.jaci.2012.08.023.View ArticlePubMedGoogle Scholar
  22. Reid DW, Misso NL, Aggarwal S, Thompson PJ, Johns DP, Walters EH: Tolerance and rebound with zafirlukast in patients with persistent asthma. J Negat Results Biomed. 2008, 7: 3-10.1186/1477-5751-7-3.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Corren J, Spector S, Fuller L, Minkwitz M, Mezzanotte W: Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. Ann Allergy Asthma Immunol. 2001, 87 (3): 211-217. 10.1016/S1081-1206(10)62228-4.View ArticlePubMedGoogle Scholar
  24. Phipatanakul W, Eggleston PA, Conover-Walker MK, Kesavanathan J, Sweitzer D, Wood RA: A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. J Allergy Clin Immunol. 2000, 105 (4): 704-710. 10.1067/mai.2000.105123.View ArticlePubMedGoogle Scholar
  25. March ME, Sleiman PM, Hakonarson H: Genetic polymorphisms and associated susceptibility to asthma. Int J Gen Med. 2013, 6: 253-265.PubMed CentralPubMedGoogle Scholar
  26. Liang R, Wang L, Wang G: New insight into genes in association with asthma: literature-based mining and network centrality analysis. Chin Med J (Engl). 2013, 126 (13): 2472-2479.Google Scholar
  27. Fu JJ, McDonald VM, Wang G, Gibson P: Asthma control: How it can be best assessed?. Curr Opin Pulm Med. 2014, 20 (1): 1-7. 10.1097/MCP.0000000000000003.View ArticlePubMedGoogle Scholar
  28. Lemiere C, Boulet LP: Cigarette smoking and asthma: a dangerous mix. Can Respir J. 2005, 12 (2): 79-80.PubMedGoogle Scholar
  29. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC: Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002, 57 (3): 226-230. 10.1136/thorax.57.3.226.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Abulhosn RS, Cai WJ: Passive smoke exposure impairs recovery after hospitalization for acute asthma. Arch Pediatr Adolesc Med. 1997, 151 (2): 135-139. 10.1001/archpedi.1997.02170390025005.View ArticlePubMedGoogle Scholar
  31. Remen T, Acouetey DS, Paris C, Zmirou-Navier D: Diet, occupational exposure and early asthma incidence among bakers, pastry makers and hairdressers. BMC Public Health. 2012, 12: 387-10.1186/1471-2458-12-387.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Lang JE, Hossain J, Smith K, Lima JJ: Asthma severity, exacerbation risk, and controller treatment burden in underweight and obese children. J Asthma. 2012, 49 (5): 456-463. 10.3109/02770903.2012.677895.View ArticlePubMedGoogle Scholar
  33. Busse W, Kraft M: Cysteinylleukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005, 127 (4): 1312-1326. 10.1378/chest.127.4.1312.View ArticlePubMedGoogle Scholar
  34. Stoloff SW: The role of LTRAs in the management of persistent asthma. Postgrad Med. 2000, 108 (4 Suppl): 22-31.PubMedGoogle Scholar

Copyright

© Chen et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement